Diabetes Drug Drives Patient Demand for Fotona 4D Non Surgical Facelift Procedure
20 Mar 2023
DALLAS--(BUSINESS WIRE)--Fotona US, the leader in the design and manufacture of high technology laser systems for aesthetics and dentistry since 1964, has noted a significant demand for Fotona 4D® Non Surgical Facelift procedures to rebuild collagen and correct sagging facial skin due to the popular off label use of a diabetes drug.
'Diabetes drugs like semaglutide injections are in high demand for rapid weight loss. Now more users are noticing an unwanted side effect: the \'Ozempic face,\' which refers to the facial aging and sagging that some users have experienced'
“Diabetes drugs like semaglutide injections are in high demand for rapid weight loss. Now more users are noticing an unwanted side effect: the 'Ozempic face,' which refers to the facial aging and sagging that some users have experienced,” states Board Certified Dermatologist Martha Viera from Coral Gables, Florida. “Even if you add back volume through fillers, the skin is not going to return right back to normal. We need to use the Fotona 4D® procedure to restore skin’s elasticity and achieve lifting and tightening to reduce the sagging, as well as restore a patient’s facial volume.”
The Fotona 4D® procedure is a series of synergistic, non-invasive laser treatments of both the exterior facial and interior oral cavity, enabling two complimentary laser wavelengths to treat 4 distinct “dimensions” of the skin to rejuvenate and tighten from the inside out. Dr. Viera adds, “It offers tightening and volumization without the need for fillers or toxins which only last between 6 and 10 months. Instead, Fotona 4D® has the ability to promote collagen production with long lasting results, therefore giving the opportunity for patients to restore and build their own collagen in a more natural manner.”
Depending on the severity of volume loss, patients can expect an initial series of 3 to 5 laser treatments over the course of a few months. Once volume is restored, it is recommended to have an additional treatment every 12-16 months to combat volume loss due to the normal aging process. Treatments are conducted in a physician’s office with minimal downtime.
According to Dimas Garcia, President and CEO of Fotona US: “Our technological innovations have created new, minimally invasive laser treatment options that patients are more motivated to take advantage of due to limited or no downtime. We have successfully maintained this approach across many other specialties, and physicians around the world use Fotona lasers to address indications from ‘head to toe,’ whether that be chronic snoring, volume and laxity throughout body, persistent melasma, and even onychomycosis, otherwise known as toe nail fungus.”
Fotona US is a world-leading medical laser company recognized for its innovative, award-winning laser systems for applications in aesthetics & dermatology, dentistry, surgery and gynecology. The company has one of the most highly educated workforces in the industry, with an exceptionally high number of PhDs specializing in laser and medical technology innovation. In addition to its direct presence in the US and EU, Fotona’s global distribution network spans across more than 70 countries, ensuring comprehensive support and service for Fotona laser users, including clinical training. www.fotona4D.com
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.